Nursing and Health Professions
Secukinumab
100%
Patient
97%
Biological Product
77%
Ustekinumab
72%
Drug
67%
Inpatient
65%
Psoriasis
50%
Survival
43%
Psoriasis Area and Severity Index
35%
Etanercept
32%
Procedures
21%
Infliximab
20%
Numbers Needed to Treat
20%
Psoriasis Vulgaris
18%
Obesity
16%
Dose
13%
Confidence Interval
12%
Body Mass
11%
Standard
10%
Socialized Medicine
10%
Time
10%
Drug Therapy
10%
Adalimumab
10%
Monotherapy
10%
Follow up
10%
Evaluation Study
10%
Decision Tree
10%
Placebo
7%
Proportional Hazards Model
6%
Kaplan Meier Method
6%
Biological Therapy
6%
Log Rank Test
6%
Multivariate Analysis
6%
Drug Withdrawal
6%
Adverse Event
5%
Clinical Outcome
5%
Clinical Practice
5%
Medicine and Dentistry
Therapeutic Procedure
81%
Ustekinumab
69%
Psoriasis
64%
Chemotherapeutic Agent
54%
Drug
54%
Survival
43%
Patient
38%
Biological Product
37%
Case Report
33%
Pustulosis Palmaris Et Plantaris
25%
Arthritis
25%
Combination Therapy
25%
Psoriasis Vulgaris
22%
Psoriasis Area and Severity Index
20%
Psoriatic Arthritis
16%
TNF Inhibitor
16%
Topical Corticosteroid
16%
Obesity
16%
Etanercept
14%
Life
12%
Adult
10%
Inpatient
8%
Follow up
8%
Adalimumab
8%
Therapy Effect
8%
Exanthem
8%
Sarcoidosis
8%
Tumor Necrosis Factor
8%
Therapeutic Agent
8%
Etretin
8%
Recurrent Disease
8%
Scalp
8%
Cyclosporine
8%
Crohn's Disease
8%
Photochemotherapy
8%
Nail
8%
Incidence
8%
Development
8%
Skin Defect
8%
Woman
8%
Log Rank Test
6%
Proportional Hazards Model
6%
Biological Therapy
6%
Kaplan Meier Method
6%
Multivariate Analysis
6%
Dermatology
6%
Drug Withdrawal
6%
Adverse Event
5%
Pharmacology, Toxicology and Pharmaceutical Science
Ustekinumab
69%
Psoriasis
64%
Drug
54%
Survival
43%
Biological Product
37%
Rheumatoid Arthritis
25%
Pustulosis palmoplantaris
25%
Psoriasis Vulgaris
22%
Tumor Necrosis Factor Inhibitor
16%
Antagonist
16%
Psoriatic Arthritis
16%
Obesity
16%
Etanercept
14%
Observational Study
12%
Retrospective Study
12%
Adalimumab
8%
Etretin
8%
Skin Defect
8%
Tumor Necrosis Factor
8%
Incidence
8%
Rash
8%
Sarcoidosis
8%
Recurrent Disease
8%
Crohn Disease
8%
Inflammatory Bowel Disease
8%
Paradoxical Reaction
8%
Ciclosporin
8%
Adverse Event
5%
